American Journal of Cardiology
Volume 107, Issue 6 , Pages 821-826 , 15 March 2011

Placental Growth Factor and B-Type Natriuretic Peptide as Independent Predictors of Risk from a Multibiomarker Panel in Suspected Acute Coronary Syndrome (Acute Risk and Related Outcomes Assessed With Cardiac Biomarkers [ARROW]) Study

  • Ruchira Glaser, MD

      Affiliations

    • Christiana Care Medical Center, Newark, Delaware
    • Corresponding Author InformationCorresponding author: Tel: 302-366-1028; fax: 302-421-9731
    • ,
  • W. Frank Peacock, MD

      Affiliations

    • Cleveland Clinic, Cleveland Ohio
    • ,
  • Alan H.B. Wu, PhD

      Affiliations

    • San Francisco General Hospital and University of California, San Francisco, San Francisco, California
    • ,
  • Reinhold Muller, PhD

      Affiliations

    • James Cook University, Townsville, Australia
    • ,
  • Martin Möckel, MD

      Affiliations

    • Charité-Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Fred S. Apple, PhD

      Affiliations

    • Hennepin County Medical Center and Department of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, Minneapolis, Minnesota

Received 19 September 2010 ,Revised 3 November 2010 ,Accepted 3 November 2010.

References 

  1. Heeschen C, Dimmeler S, Fichtlscherer S, Hamm CW, Berger J, Simoons ML, et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA. 2004;291:435–441
  2. Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, Tate J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005;51:810–824
  3. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, et al. Multimarker approach to risk stratification in non-ST-elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760–1763
  4. Eggers KM, Lagerqvist B, Venge P, Wallentin L, Lindahl B. Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2009;54:357–364
  5. Wang TY, AlJaroudi WA, Newby LK. Markers of cardiac ischemia and inflammation. Cardiol Clin. 2005;23:491–501
  6. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631–2639
  7. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107–2116
  8. Apple FS, Pearce LA, Chung A, Ler R, Murakami MM. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem. 2007;53:874–881
  9. Thygesen K, Alpert JS, White HD Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525–2538
  10. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361:858–867
  11. Yue B, Pattison E, Roberts WL, Rockwood AL, Danne O, Lueders C, et al. Choline in Whole Blood and Plasma: Sample Preparation and Stability. Clin Chem. 2008;54:590–593
  12. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766–772
  13. Muller R, Möckel M. Logistic regression and CART in the analysis of multimarker studies. Clin Chim Acta. 2008;394:1–6
  14. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, et al. B-Type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis. 2005;46:610–620
  15. Apple FS, Pearce LA, Doyle PJ, Otto AP, Murakami MM. Cardiac troponin risk stratification based on 99th percentile reference cutoffs in patients with ischemic symptoms suggestive of acute coronary syndrome: influence of estimated glomerular filtration rates. Am J Clin Pathol. 2007;127:598–603
  16. Agarwal R. The challenge of discovering patient-level cardiovascular risk factors in chronic kidney disease. Kidney Int. 2008;73:1340–1342
  17. Gibson CM, Raphaelle L, Dumaine EV, Gelfand SA, Murphy M, Morrow DA, et al. Association of glomerular filtration rate on presentation with subsequent mortality in non–ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004;25:1998–2005
  18. Wong JA, Goodman SG, Yan RT, Wald R, Bagnall AJ, Welsh RC, et al. Temporal management patterns and outcomes of non–ST elevation acute coronary syndromes in patients with kidney dysfunction. Eur Heart J. 2009;30:549–557
  19. DeFilippi C, van Kimmenade RR, Pinto YM. Aminoterminal pro-B-type natriuretic peptide testing in renal disease. Am J Cardiol. 2008;101:82–88
  20. Das SR, Abdullah SM, Leonard D, Drazner MH, Khera A, McGuire DK, et al. Association between renal function and circulating levels of natriuretic peptides (from the Dallas Heart Study). Am J Cardiol. 2008;102:1394–1398
  21. Apple FS, Murakami MM, Pearce LA, Herzog CA. Prognostic value of high sensitivity C-reactive protein, N-terminal proBNP, and cardiac troponin T and I in end stage renal disease for subsequent death over two years. Clin Chem. 2004;50:2279–2285
  22. Haapio M, Ronco C. BNP and a renal patient: emphasis on the unique characteristics of B-type natriuretic peptide in end-stage kidney disease. Contrib Nephrol. 2008;161:68–75
  23. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595–1604
  24. Peacock WF, Nagurney J, Diercks DB, Birkhahn R, Chandra A, Counselman F, et al. Myeloperoxidase in the Diagnosis of Acute Coronary Syndromes (MIDAS) trial. Acad J Emerg Med. 2010;17(suppl):S195

 The Acute Risk and Related Outcomes Assessed With Cardiac Biomarkers (ARROW) study was sponsored and funded by Abbott Laboratories, Abbott Park, Illinois.

PII: S0002-9149(10)02405-7

doi: 10.1016/j.amjcard.2010.11.003

American Journal of Cardiology
Volume 107, Issue 6 , Pages 821-826 , 15 March 2011

Article Tools

* Image Usage & Resolution